

Randomized, controlled study on the use of simvastatin in mild cognitive disorders

<https://neurodegenerationresearch.eu/survey/randomized-controlled-study-on-the-use-of-simvastatin-in-mild-cognitive-disorders/>

Principal Investigators

Heuser

Institution

Charité - Universitätsmedizin Berlin

Contact information of lead PI

Country

Germany

Title of project or programme

Randomized, controlled study on the use of simvastatin in mild cognitive disorders

Source of funding information

Federal Ministry of Education and Research (BMBF)

Total sum awarded (Euro)

€ 3,996,098

Start date of award

01/11/2008

Total duration of award in years

10.3

The project/programme is most relevant to:

Alzheimer's disease & other dementias

Keywords

Research Abstract

Purpose: Probands with MCI are at high risk to develop Alzheimer's dementia (AD). Simvastatin may lower the production of Amyloid, a hallmark of AD in the brain. The primary hypothesis of the study is that 60 mg Simvastatin significantly reduces the Clinical Dementia Rating -Sum of boxes (CDR-SOB) in individuals with MCI as compared to MCI receiving placebo or 20 mg Simvastatin

Lay Summary

Further information available at:

Types:

Investments > €500k

Member States:

Germany

Diseases:

Alzheimer's disease & other dementias

Years:

2016

Database Categories:

N/A

Database Tags:

N/A